Search results
Results from the WOW.Com Content Network
The Combat Methamphetamine Epidemic Act of 2005 (CMEA) is federal legislation enacted in the United States on March 9, 2006, to regulate, among other things, retail over-the-counter sales of following products because of their use in the manufacture of illegal drugs: ephedrine; pseudoephedrine
As a result of the U.S. Combat Methamphetamine Epidemic Act of 2005 (CMEA), which was passed as an amendment to the renewal of the USA PATRIOT Act, [17] there are restrictions on the amount of pseudoephedrine and ephedrine one may purchase in a specified time period and further requirements that these products must be stored in order to prevent ...
Congress passed the Combat Methamphetamine Epidemic Act of 2005 (CMEA) as an amendment to the renewal of the USA Patriot Act. [138] Signed into law by President George W. Bush on 6 March 2006, [137] the act amended 21 U.S.C. § 830, concerning the sale of pseudoephedrine-containing products. The law mandated two phases, the first needing to be ...
Because it contains pseudoephedrine, its purchase in the United States was severely restricted by the Combat Methamphetamine Epidemic Act of 2005 over fears that any product containing pseudoephedrine can be used to make methamphetamine. [1]
(Reuters) - The European Medicines Agency's (EMA) safety committee on Friday recommended changes to product information for all medicines that contain the ingredient pseudoephedrine to address ...
Things got a little stickier in 2006, when the Combat Methamphetamine Epidemic Act was signed. This law banned the sale of over-the-counter medications that contain pseudoephedrine (a decongestant ...
The FDA assembled its outside advisers to take another look at phenylephrine, which became the main drug in over-the-counter decongestants when medicines with an older ingredient ...
The House passed the Combat Methamphetamine Epidemic Act of 2005 as an amendment to the renewal of the USA PATRIOT Act. Signed into law by President George W. Bush on March 6, 2006, the act amended the US Code (21 USC 830) concerning the sale of products containing ephedrine and the closely related drug pseudoephedrine.